Certainty index
High certainty — page 2
The Institute is confident that the true effect lies close to the estimate. Further research is very unlikely to change confidence in the estimate.
Graded outcomes
62 documents · page 2 of 2
Table 1. Outcomes and syntheses graded at high certainty, on this page.
| Document | Type | Effect or conclusion as recorded |
|---|---|---|
| Dulaglutide in type 2 diabetes mellitus: tolerability and discontinuation | Synthesis | High certainty evidence from 7 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather than… |
| Semaglutide in type 2 diabetes mellitus: tolerability and discontinuation | Synthesis | High certainty evidence from 7 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather than… |
| Tirzepatide in type 2 diabetes mellitus: tolerability and discontinuation | Synthesis | High certainty evidence from 7 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather than… |
| Exenatide in type 2 diabetes mellitus: tolerability and discontinuation | Synthesis | High certainty evidence from 5 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather than… |
| Lixisenatide in type 2 diabetes mellitus: tolerability and discontinuation | Synthesis | High certainty evidence from 4 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather than… |
| Exenatide in atherosclerotic cardiovascular disease and cardiovascular risk reduction: tolerability and… | Synthesis | High certainty evidence from 3 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather than… |
| Liraglutide in obesity and overweight in adults: tolerability and discontinuation | Synthesis | High certainty evidence from 3 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather than… |
| Semaglutide, oral in type 2 diabetes mellitus: tolerability and discontinuation | Synthesis | High certainty evidence from 3 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather than… |
| Dulaglutide in atherosclerotic cardiovascular disease and cardiovascular risk reduction: tolerability and… | Synthesis | High certainty evidence from 2 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather than… |
| Liraglutide in type 2 diabetes mellitus: tolerability and discontinuation | Synthesis | High certainty evidence from 2 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather than… |
| Semaglutide in atherosclerotic cardiovascular disease and cardiovascular risk reduction: tolerability and… | Synthesis | High certainty evidence from 2 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather than… |
| Tirzepatide in obstructive sleep apnoea with obesity: tolerability and discontinuation | Synthesis | High certainty evidence from 2 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather than… |
| Tirzepatide in obesity and overweight in adults: durability of effect | Synthesis | High certainty evidence bears on whether the effect of Tirzepatide in obesity and overweight in adults is maintained across the randomised period. The contributing trials range in duration and the… |
| Semaglutide in obesity and overweight in adults: durability of effect | Synthesis | High certainty evidence bears on whether the effect of Semaglutide in obesity and overweight in adults is maintained across the randomised period. The contributing trials range in duration and the… |
| Dulaglutide in type 2 diabetes mellitus: durability of effect | Synthesis | High certainty evidence bears on whether the effect of Dulaglutide in type 2 diabetes mellitus is maintained across the randomised period. The contributing trials range in duration and the Institute… |
| Semaglutide in type 2 diabetes mellitus: durability of effect | Synthesis | High certainty evidence bears on whether the effect of Semaglutide in type 2 diabetes mellitus is maintained across the randomised period. The contributing trials range in duration and the Institute… |
| Tirzepatide in type 2 diabetes mellitus: durability of effect | Synthesis | High certainty evidence bears on whether the effect of Tirzepatide in type 2 diabetes mellitus is maintained across the randomised period. The contributing trials range in duration and the Institute… |
| Exenatide in type 2 diabetes mellitus: durability of effect | Synthesis | High certainty evidence bears on whether the effect of Exenatide in type 2 diabetes mellitus is maintained across the randomised period. The contributing trials range in duration and the Institute… |
| Lixisenatide in type 2 diabetes mellitus: durability of effect | Synthesis | High certainty evidence bears on whether the effect of Lixisenatide in type 2 diabetes mellitus is maintained across the randomised period. The contributing trials range in duration and the Institute… |
| Exenatide in atherosclerotic cardiovascular disease and cardiovascular risk reduction: durability of effect | Synthesis | High certainty evidence bears on whether the effect of Exenatide in atherosclerotic cardiovascular disease and cardiovascular risk reduction is maintained across the randomised period. The… |
| Liraglutide in obesity and overweight in adults: durability of effect | Synthesis | High certainty evidence bears on whether the effect of Liraglutide in obesity and overweight in adults is maintained across the randomised period. The contributing trials range in duration and the… |
| Semaglutide, oral in type 2 diabetes mellitus: durability of effect | Synthesis | High certainty evidence bears on whether the effect of Semaglutide, oral in type 2 diabetes mellitus is maintained across the randomised period. The contributing trials range in duration and the… |
page 2 of 2